Published in BMC Med Res Methodol on June 16, 2003
Causal inference, probability theory, and graphical insights. Stat Med (2013) 1.69
Simpson's paradox visualized: the example of the rosiglitazone meta-analysis. BMC Med Res Methodol (2008) 1.00
Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials. Haematologica (2010) 0.91
Early reporting for cancer screening trials. J Med Screen (2008) 0.79
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med (2002) 8.72
Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Annu Rev Public Health (2000) 4.20
Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med (1997) 4.08
Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. Stat Med (2002) 2.86
The paired availability design: a proposal for evaluating epidural analgesia during labor. Stat Med (1994) 2.71
Choice of effect measure for epidemiological data. J Clin Epidemiol (2000) 2.49
Statistics and medical experimentation. Biometrics (1975) 1.41
Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies. J Womens Health Gend Based Med (2001) 1.41
Rethinking historical controls. Biostatistics (2001) 1.21
The paired availability design for historical controls. BMC Med Res Methodol (2001) 1.13
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Screening for prostate cancer with PSA testing: current status and future directions. Oncology (Williston Park) (2011) 2.26
Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol (2002) 2.26
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med (2009) 1.94
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol (2010) 1.91
The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer (2013) 1.76
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
Identifying genes that contribute most to good classification in microarrays. BMC Bioinformatics (2006) 1.60
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. Ann Intern Med (2014) 1.56
Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol (2003) 1.52
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
The word "cancer": how language can corrupt thought. BMJ (2013) 1.51
A perfect correlate does not a surrogate make. BMC Med Res Methodol (2003) 1.45
A population approach to precision medicine. Am J Prev Med (2012) 1.44
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. J Clin Oncol (2008) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics (2004) 1.27
Statistical issues in randomized trials of cancer screening. BMC Med Res Methodol (2002) 1.27
Biomarkers, subgroup evaluation, and clinical trial design. Discov Med (2012) 1.21
National Children's Study: update in 2010. Mt Sinai J Med (2011) 1.17
Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer (2009) 1.15
Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates. Biostatistics (2005) 1.15
Cancer screening campaigns--getting past uninformative persuasion. N Engl J Med (2012) 1.14
Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int (2007) 1.13
The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"? BMC Med Res Methodol (2004) 1.11
Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer (2007) 1.10
Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer (2007) 1.09
Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen. Cancer (2005) 1.08
Simple maximum likelihood estimates of efficacy in randomized trials and before-and-after studies, with implications for meta-analysis. Stat Methods Med Res (2005) 1.08
The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol (2002) 1.08
Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology (2006) 1.07
Cancer screening in theory and in practice. J Clin Oncol (2005) 1.06
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2006) 1.01
Estimating the cumulative risk of false positive cancer screenings. BMC Med Res Methodol (2003) 0.98
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Med Res Methodol (2003) 0.98
The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource. J Natl Cancer Inst (2013) 0.98
5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review. BJU Int (2010) 0.97
A simple method for analyzing data from a randomized trial with a missing binary outcome. BMC Med Res Methodol (2003) 0.91
Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen (2011) 0.89
Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol (2004) 0.88
Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen (2008) 0.87
Surrogate endpoint analysis: an exercise in extrapolation. J Natl Cancer Inst (2012) 0.86
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics (2010) 0.86
Future directions for postdoctoral training in cancer prevention: insights from a panel of experts. Cancer Epidemiol Biomarkers Prev (2014) 0.85
Systems biology and cancer: promises and perils. Prog Biophys Mol Biol (2011) 0.85
Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics. Semin Cancer Biol (2008) 0.82
Clarifying the role of principal stratification in the paired availability design. Int J Biostat (2011) 0.81
The risky reliance on small surrogate endpoint studies when planning a large prevention trial. J R Stat Soc Ser A Stat Soc (2012) 0.80
Randomized trials for the real world: making as few and as reasonable assumptions as possible. Stat Methods Med Res (2007) 0.80
Early reporting for cancer screening trials. J Med Screen (2008) 0.79
Clinical trial design and evidence-based outcomes in the study of liver diseases. J Hepatol (2009) 0.79
Evaluating a new marker for risk prediction: decision analysis to the rescue. Discov Med (2012) 0.78
Development tracks for cancer prevention markers. Dis Markers (2004) 0.78
The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results. Rev Recent Clin Trials (2015) 0.76
The randomized registry trial. N Engl J Med (2014) 0.76
The Mayo Lung Project lung cancer mortality findings are unlikely to be biased by a volunteer effect. Eur J Epidemiol (2011) 0.75
Colorectal cancer prevention and fishful thinking. J Natl Cancer Inst (2015) 0.75
Comprehensive Quality Management (CQM) in the PLCO Trial. Rev Recent Clin Trials (2015) 0.75
Screening for prostate cancer: current status and future prospects. Am J Med (2007) 0.75